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Abstract
Background: Neuroendocrine (NE) differentiation in prostate cancer has been correlated with a poor prognosis and 
hormone refractory disease. In a previous report, we demonstrated the presence of immunoreactive cytoplasmic 
hypoxia inducible factor 1α (HIF1α), in both benign and malignant NE prostate cells. HIF1α and HIF1β are two subunits 
of HIF1, a transcription factor important for angiogenesis. The aim of this study was to elucidate whether the 
cytoplasmic stabilization of HIF1α in androgen independent NE differentiated prostate cancer is due to the presence of 
certain HIF1α isoforms.
Methods: We studied the HIF1α isoforms present in 8 cases of benign prostate hyperplasia (BPH) and 43 cases of 
prostate cancer with and without NE differentiation using RT-PCR, sequencing analysis, immunohistochemistry and in 
situ hybridization.
Results: We identified multiple isoforms in both benign and malignant prostate tissues. One of these isoforms, 
HIF1α1.2, which was previously reported to be testis specific, was found in 86% of NE-differentiated prostate tumors, 
92% of HIF1α immunoreactive prostate tumors and 100% of cases of benign prostate hyperplasia. 
Immunohistochemistry and in situ hybridization results showed that this isoform corresponds to the cytoplasmic HIF1α 
present in androgen-independent NE cells of benign and malignant prostate tissue and co-localizes with 
immunoreactive cytoplasmic HIF1β.
Conclusion: Our results indicate that the cytoplasmic stabilization of HIF1α in NE-differentiated cells in benign and 
malignant prostate tissue is due to presence of an HIF1α isoform, HIF1α1.2. Co-localization of this isoform with HIF1β 
indicates that the HIF1α1.2 isoform might sequester HIF1β in the cytoplasm.
Background
Neuroendocrine (NE) cells in benign and malignant pros-
tate tissue are characterized by expression of the NE
marker chromogranin A and their specific morphology,
including cytoplasmic extensions and dendritic pro-
cesses. In addition, they lack androgen receptor and are
therefore androgen-independent [1,2]. The majority of
prostatic adenocarcinomas contain tumor cells with NE
features which are present focally throughout the tumors.
Several studies have shown that an increased number of
NE cells in prostate cancer tissue and increased levels of
circulating chromogranin A, an NE marker usually
expressed in NE cells, are associated with a poor progno-
sis, tumor progression and androgen-independent dis-
ease [1,2]. It has been hypothesized that NE cells might
affect the growth and proliferation of prostate tumors in
an androgen receptor-independent way, probably
through the secretion of NE peptides and autocrine/para-
crine signaling pathways [1,3-6]. NE tumor cells in pros-
tate cancer may also have a role in tumor angiogenesis.
Increased expression of vascular endothelial growth fac-
tor (VEGF) in malignant NE cells and a higher density of
microvessels around nests of such cells compared to areas
of prostate cancer without these cells have been reported
[7]. In a previous study, we demonstrated the presence of
cytoplasmic hypoxia inducible factor 1α (HIF1α) in a
population of NE cells in benign and malignant prostate
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Page 2 of 9tissues [8]. HIFs are a family of transcription factors that
are essential for angiogenesis and the adaptation of cells
to hypoxia in both physiological and pathological pro-
cesses [9,10]. The possible mechanisms behind HIF1α
stabilization and the function of cytoplasmic HIF1α in
NE cells of benign and malignant prostate tissues are not
known. However, the complicated regulation of HIFs has
been extensively studied in recent years. HIF1, which is
composed of two subunits, HIF1α and β, binds to the
HRE of promoter regions and activates many genes
involved in angiogenesis, glycolysis and anaerobic metab-
olism. In normoxia, the HIF1α subunit is hydroxylated on
specific proline residues (402 and 564) within the oxygen
dependent domain (ODD) by specific oxygen-sensitive
prolyl hydroxylases and, then ubiquitinated through the
von Hippel-Lindau (VHL) dependent pathway and
degraded instantly in the proteasome [9,10]. However, in
hypoxic conditions, HIF1α is stabilized by impaired func-
tion of these prolyl hydroxylases. After its interaction
with a series of small proteins, such as P300 and CBP, the
HIF1α and β complex translocates to the nucleus using its
nuclear localizing signal (NLS) domains at C-and N-ter-
minus and activates the cell's adaptive response to
hypoxia [9,10]
There have been several previous reports on HIF1α iso-
forms lacking several exons or displaying different exons
than the wild type protein. Some of these isoforms
encode cytoplasmic HIF1α protein or proteins with
altered transcriptional activity compared to the wild type
protein. Regarding the N-terminal domain, two HIF1α
isoforms with different first exons have been identified:
HIF1α1.2, a protein with a different first and second exon
which is 59 amino acids shorter than wild type HIF1α and
encodes a cytoplasmic protein specifically expressed in
the human testis [11]; HIF1α1.3, which is present in acti-
vated T-lymphocytes and encodes a functional protein
with weaker transcriptional activity that the wild type
protein [12]. At the C-terminal domain, isoforms lacking
either exon 12 [13] or exons 11 and 12 [14] have been
reported. Both isoforms have been shown to be stable
cytoplasmic proteins and inhibit the function of full-
length HIF1α. Another shorter HIF1α isoform lacking
exon 14 has also been reported [15]. This isoform was
shown to be 3-fold less active than full-length HIF1α.
The aim of this study was to elucidate the mechanism
behind the cytoplasmic stabilization of HIF1α in NE cells
of benign and malignant prostate tissues. We have inves-
tigated whether the cytoplasmic HIF1α corresponds to
any specific known isoform. Based on the sequences pub-
lished by the National Center for Biotechnology Informa-
tion (NCBI), we designed primers to amplify known
HIF1α isoforms and determined their presence in benign
prostate hyperplasia and prostate cancer with and with-
out NE differentiation.
Methods
Study cases
The present study included tissue obtained from 51
patients undergoing transurethral resection of the pros-
tate (TURP): From 8 patients with obstructive voiding
symptoms due to benign hyperplasia of the prostate
(BPH), and from 43 patients with prostate cancer. The
majority of the patients in the latter group had previously
received therapy and displayed hormone-refractory dis-
ease (Table 1). All tissue specimens were examined by a
National Board certified pathologist (NM). This study
was approved by the Ethics Committee of Lund Univer-
sity, and the Helsinki Declaration regarding the use of
human tissue was followed.
RNA preparation, RT-PCR and sequence analysis
Total RNA was extracted from prostate tissue using TRI-
zol reagent (Invitrogen, Carlsbad, CA), and cDNA syn-
thesis was conducted as described previously. To detect
isoforms of HIF1α, PCR was performed with the primer
sets shown in Table 2. The 50-μl reaction volume con-
tained 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 1.5 mM
Table 1: Characteristics of patients whose samples were 
used in this study
Nr. of cases
Age
<65 7
≥65 44
Benign prostate hyperplasia 8
Adenocarcinoma 43
Gleason Score
5 1
6 2
7 11
8 3
9 13
10 3
Non - determined 10
Clinical stage
T1 3
T2 12
T3 19
T4 2
Non - determined 7
Hormone refractory 
adenocarcinoma
30
Adenocarcinoma with non 
determined hormonal state
13
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Page 3 of 9MgCl2, 0.2 mM of each dNTP, 1 unit Platinum Taq DNA
polymerase (Invitrogen), 10 μM of each of the forward
and reverse primers and 1 μl of cDNA. After an initial
denaturation at 94°C for 5 min, 40 cycles of 1 min at 94°C,
1 min at 56°C and 1 min at 72°C were run using a Master
cycler gradient (Eppendorf-Netheler. Hinz GmbH, Ham-
burg, Germany) termam cycler. The size of the amplified
PCR product was determined on an agarose gel with 1 kb
DNA ladder (cat. no. 15615-024, Invitrogen) and. For
sequence analysis, the amplified fragments were purified
using the Qiagen PCR purification kit (Qiagen),
sequenced using the dideoxy procedure with an ABI
Prism Big Dye terminator v1.1 cycle sequencing kit (PE
Applied Biosystems) and the same primers as for PCR on
an Applied Biosystems Model 3100-Avant Genetic Ana-
lyzer.
In situ hybridization
Biotinylated anti sense and sense olignucleotide probes
were designed and purchased from Invitrogen (Table 2).
Tissues were fixed in 4% formaldehyde, 4-μm-thick sec-
tions were cut and mounted on silanized slides (DAKO
S3003), dewaxed with xylene for 10 min and rehydrated
stepwise with 100% ethanol for 3 min and 70% ethanol for
3 min. Endogenous peroxidase and biotin were blocked
with peroxidase blocking solution (DAKO REAL, S2023)
and biotin blocking system (DAKO, X0590) for 15 min
each. The sections were then permeabilized with Protei-
nase K (DAKO S3020) and washed with Tris-buffered
saline three times. Biotinylated probes designed for
HIF1α1.2 (Table 2, Invitrogen) were mixed in hybridiza-
tion buffer (50% formamide) at a concentration of 200 ng/
ml. Probes were added to the sections, which were then
covered with coverslips and heated at 92°C for 5 min.
Hybridization was carried out in a humid chamber at
37°C overnight. The sections were then washed in 2 ×
SSC for 10 min followed by three washes in Tris-buffered
saline. For detection of hybridization signals, the Gen
Point Tyramid Signal Amplification System (Dako,
K0620) with chromogenic substrate (3.3'diaminobenzi-
dine) was used according to the manufacturer's instruc-
tions.
Immunohistochemistry
Tissue samples were fixed in 4% buffered formalin and
embedded in paraffin. One appropriate block from each
specimen was selected and serial 4-μm-thick sections of
tissue measuring at least 0,5 × 0,5 cm was cut from the
paraffin lock. The sections were used for immunohis-
tochemical analysis and histological examination after
hematoxylin and eosin staining. After deparaffinization
and rehydration, the sections were heated in citrate buffer
solution (pH 6) for 14 min in a microwave oven for anti-
gen retrieval. The characteristics and working concentra-
tions of the antibodies used in this study are summarized
in Table 3. Three primary HIF1α antibodies with different
epitopes were chosen; polyclonal antibody (AB1, Y-15,
santa cruz) recognizing an epitope near the N-terminus
of wild type HIF1α, monoclonal HIF1α (Ab2, Novus Bio-
logical, NB 100-123), which recognizes an epitope in the
middle of wild type HIF1α (residues 432-528, corre-
sponding to exon 10 and 11 of HIF1α protein) and poly-
clonal HIF1α (Ab3, Bethyl Laboratories), which
recognizes a region between residues 775 and the C-ter-
minus (residue 826), corresponding to the exon 14 of
HIF1α protein. Chromogranin A was chosen as NE mark-
ers, and a polyclonal anti-chromogranin A antibody
(DAKO, Denmark) was used. Immunohistochemical
staining was carried out with LSAB+ System (HRP,
K0670, DAKO, Denmark), according to the manufac-
turer's instructions. Sections were incubated with pri-
mary antibody at room temperature for 60 min.
Counterstaining was done with Mayer hematoxylin.
Tumors with chromogranin A immunopositivity were
considered NE-differentiated. The smallest chromogra-
nin A immunopositive tumor area, detected in our study
cases, contained 10 immunostained cells.
Double immunostaining was performed with combina-
tions of primary antibodies for androgen receptor/chro-
Table 2: Primers used for amplification/sequencing and biotinylated oligonucleotide probes
Forward primer 5'-3' Reverse primer 5'-3' Size of amplified 
fragment lengths (bp)
HIF1α 1.1 CACCTCTGGAC TTGCCTTTCCTTC CACCAGCATCCAG AAGTTTCCTCAC 351
aHIF1α 1.2 ATGTGCAAGAC ACTGCATTCTTAG CACCAGCATCCAG AAGTTTCCTCAC 220
HIF1α 1.3 TGGTGGTTACTC AGCACTTTTAGA CACCAGCATCCAG AAGTTTCCTCAC -
HIF1α 10-13 GGCAATGTCTCC ATTACCCACCG CGCTTTCTCTGAGC ATTCTGCAAG 791
HIF1α12 GGTGGCATTACG AGTAGGTTCTTGT AGGTCCCTATATC CCAATGGATGA 180
HIF1α 13-15 ACTCAAAGTCGG ACAGCCTCACCA ATCCATTGATTGC CCCAGCAGTC 381
Probe HIF1α 1.2 Antisense, Biotin-GC AAGATATGTG CAAGACAC-
Biotin
Sense, Biotin-GTGT CTTGCACAT ATCTTGC-
Biotin
-
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staining kit (PicTure™ Invitrogen, catalog nr. 87-9999) was
used, according to the manufacturer's instructions. Goat
anti mouse IgG HRP (horseradish peroxidase) conjugate
used with DAB (3,3' Diaminobenzidine) produced a
brown stain. Goat anti Rabbit IgG-AP polymer conjugate
used with Fast red produced a red stain.
Results
A broad range of HIF1α isoforms exists in benign and 
malignant prostate tissues
HIF1α1.1 isoform was present in both benign and malig-
nant prostate tissues (Table 4, Fig.1a). HIF1α1.2 was
detected in 25 out of 43 cases of prostate cancer and in all
cases of benign prostate hyperplasia (Table 4, Fig.1b).
This isoform was expressed variably, although the signals
from benign prostate tissues were very weak (Fig. 1b). We
also found a correlation between this isoform and NE dif-
ferentiation in prostate tumors. Eighty sex percent of
prostate tumors with NE (compared to 28% of prostate
tumors without NE) expressed this isoform (Table 4).
Comparing the presence of this isoform with HIF1α
immunostaining showed that 92% of cases with this iso-
form also showed HIF1α immunostaining (Table 4).
Therefore, we suspect that the HIF1α1.2 isoform repre-
sents the cytoplasmic HIF1α in NE cells. The weak sig-
nals from benign prostate tissue can be explained by the
fact that NE cells are rare in benign prostate tissue, mak-
ing up only about 10% of the cells in the prostate gland. In
addition, we used non-NE-differentiated LNCaP cells as a
control, and these cells did not express this isoform, fur-
ther indicating that it represents cytoplasmic HIF1α (Fig.
1g, lane 2).
HIF1α 1.3 was not detected in any of our study cases
(Table 4, Fig.1c). Since inflammation was rare in our
specimen, this further verifies a report showing the pres-
ence of this isoform of HIF 1α in activated lymphocytes.
However, we lacked positive control for HIF1α1.3.
Tο investigate various isoforms with alternative splic-
ing of exons 11 to 13, we used forward primers located in
the middle of exon 10 and reverse primers located in the
middle of exon 13. We noted one strong band of 220 bp
and a weaker band of 340 bp (Fig. 1d). Sequence analysis
of the shorter band showed only part of exons 10 and 13,
indicating the presence of an HIF1α isoform without
exons 11 and 12. Sequence analysis of the weaker band of
340 bp was not possible, but the size of the band corre-
sponds to an isoform lacking exon12. These two isoforms
were found in both benign and malignant cases. In one
case of benign prostate hyperplasia and three cases of
malignant prostate tissue, we also detected a band at 720
bp, which might correspond to HIF1α containing exons
11 and 12. As a control, we analyzed LNCaP cells, which
showed a strong band of 720bp (Fig. 1g, lane 5). Sequence
analysis verified that the band corresponds to exons 10,
11 and 12 as well as a part of exon 13.
To further investigate the presence of exon 12 in benign
and malignant prostate tissues, we designed primers
located in the beginning and end of exon 12 (Table 2). We
identified exon 12 in all study cases (Fig. 1e). We conclude
that the first experiment using primers located in exons
10 and 13 was not optimal to detect the longer HIF1α iso-
form containing exon 12. We also conclude that in most
cases of benign prostate hyperplasia and prostate can-
cers, the HIF1α isoform containing exon 12 is expressed
at very low levels since LNCaP cells had high signals with
the same primers (Fig. 1g, lane 5).
HIF1α variants with and without exon 14 (HIF1α14+
and 14-) were detected in all cases of benign prostate
hyperplasia and prostate cancer. With primers located in
Table 3: Antibodies used for immunostaining
Antibodies Clone/Code Dilution Source
HIF1α, Ab1 Goat
polyclonal
Y-15
1:50 Santa Cruz
HIF1α, Ab2 Mouse
monoclonal,
NB 100-123
1:1000 Novus biological
HIF1α, Ab3 Rabbit
polyclonal
1:500 Bethyl laboratories
HIF1β Mouse
monoclonal,
ab465-100
1:100 Abcam
Androgen receptor, AR Mouse monoclonal
AR441
1:1000 DAKO
Chromogranin A Rabbit polyclonal
IHC00460
1:1000 DAKO
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Figure 1 RT-PCR analysis of HIF1α mRNA isoforms in benign prostate hyperplasia (B, Fig. 1a-f), NE differentiated prostate cancer (M1, 
Fig.1a-f)) and non NE differentiated prostate cancer (M2, Fig. 1a-f)). K (Fig. 1a-f) and T (Fig. 1b) correspond to control and testis tissue, respectively. 
HIF1α isoforms in LNCaP cells (Fig. 1g), Lane 1 represents HIF1α1.1, lane 2 represents HIF1α1.2, and lane 3 represents HIF1α1.3. Lane 4: bands detected 
with primers sets located in exons 10 and 13, lane 5 includes bands from primers located in exon 12 and lane 6 corresponds to bands detected with 
primers located in exons 13 and 15
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Table 4: The frequency of HIF1α isoforms in benign prostate hyperplasia and prostate cancer with and without NE.
Table 4 Total nr. HIF1α 1.1 HIF1α 1.2 HIF1α 1.3 HIF1α 12+ HIF1α 12- HIF1α 11-&12- HIF1α 14+ HIF1α 14-
Benign 8 8 (100%) 8 (100%) 0 8 (100%) 8 (100%) 8 (100%) 8 (100%) 8 (100%)
Adenocarcinoma 43 43 (100%) 25 (58%) 0 43 (100%) 43 (100%) 43 (100%) 43 (100%) 43 (100%)
Adenocarcinoma immunopositive for HIF1α 26 26 (100%) 24 (92%) 0 26 (100%) 26 (100%) 26 (100%) 26 (100%) 26 (100%)
Adenocarcinoma immunonegative for HIF1α 17 17 (100%) 1 (6%) 0 17 (100%) 17 (100%) 17 (100%) 17 (100%) 17 (100%)
Adenocarcinoma with NE 22 22 (100%) 19 (86%) 0 22 (100%) 22 (100%) 22 (100%) 22 (100%) 22 (100%)
Adenocarcinoma Without NE 21 21 (100%) 6 (28%) 0 21 (100%) 21 (100%) 21 (100%) 21 (100%) 21 (100%)
LNCaP + - - + + + + +
The LNCaP cells were used as a control
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Page 7 of 9exons 13 and 15, we detected two bands corresponding to
these two isoforms (Fig. 1f).
LNCaP cells were used as control for analysis of
HIF1α1.1, HIF1α12+/-, and HIF1α14+/-. HIF1α 1.2 and
1.3 were not detected in these cells (Fig. 1g, lanes 1,2,3
and 6).
Cytoplasmic HIF1α in NE cells from prostate tumors has an 
different N-terminus than the wild type protein
To differentiate the isoforms of HIF1α, we used three dif-
ferent antibodies that recognize the N-terminus of wild
type protein (Y-10 Santa Cruz, Ab1, corresponding to
exons 1-2, Figs.2a and 2c), the middle section of wild type
protein (NB 100-123, Ab2, corresponding to exons 10-11,
Figs. 2a,b,d) and the C-terminus (Bethyl Laboratories
Ab3, corresponding to exon 14, Figs. Fig. 2a,b,e). Immu-
nostaining was performed on serial sections of benign
prostate hyperplasia and HIF1α prostate cancer tissues.
The antibody recognizing the N-terminus of wild type
HIF1α failed to detect cytoplasmic HIF1α in malignant
cells of prostate tissue (Fig.2c), whereas positive immu-
nostaining was seen with the other two antibodies (Figs.
2d and 2e). The same results were shown with benign
prostate tissue (Not shown). These results indicate that
the cytoplasmic HIF1α detected in the NE cells of benign
and malignant cells contains an N-terminal portion dif-
ferent from the wild type protein.
Co-localization of HIF1α and HIF1β in androgen receptor-
negative benign and malignant NE-like cells of the prostate
Immunostaining for HIF1β showed cytoplasmic staining
in NE-like cells of benign prostate tissue (Fig. 2i). In order
to investigate whether the immunoreactive HIF1β co-
localizes with HIF1α in benign prostate tissue, we
selected two cases of benign prostate hyperplasia for dou-
ble immunostaining. We observed co-localization of
cytoplasmic HIF1α with cytoplasmic HIF1β in all NE
cells of the benign prostate tissue (53 cells counted) (Fig.
2j). We also investigated the localization of HIF1α and
HIF1β using immunostaining of serial sections of two
cases with NE and non-NE prostate tumors. HIF1β was
seen in approximately 80%-100% of HIF1α-positive NE-
differentiated tumor cells (Figs. 2e and 2f). In addition,
double staining in malignant HIF1α-immunopositive
cells showed that these cells were immunonegative for
androgen receptor (Fig. 2g). In non-NE prostate tumors
we found no detectable cytoplasmic HIF1β immunos-
taining. Only weak nuclear HIF1β staining was observed
in these tumors (data not shown).
In situ hybridization shows the presence of HIF1.2α in NE-
differentiated benign and malignant prostate cells
In situ hybridization was performed on serially cut paraf-
fin sections from two cases of benign and four cases of
malignant prostate cancer. Two cases of adenocarcino-
mas were previously shown to contain cells with cyto-
plasmic HIF1α and NE marker, chromogranin. The other
two cases were negative for cytoplasmic HIF1α and NE
marker. In adjacent sections, the majority of HIF1α posi-
tive cells in both benign and malignant cells (93% versus
89%) also displayed increased HIF1α1.2 specific mRNA
levels (Figs. 3a,c, g, i, j). Fifty cells were counted in the
benign cases, and 300 cells were counted in the malignant
tissue. The HIF1α-negative cells had low or no detectable
mRNA levels of HIF1α (Figs. 3e and 3f). These findings
suggest that HIF1α1.2 corresponds to the isoform encod-
ing cytoplasmic HIF1α in both benign and malignant
prostate tissues.
Discussion
HIF1α, a major transcription factor essential in tumori-
genesis, has been shown to be over-expressed in many
types of tumors, including prostate cancer [16-18]. Neo-
Figure 2 Schematic demonstration of the three HIF1α antibodies 
used in this study and their epitopes (Figs. 2a and b). Ab1 is a poly-
clonal antibody raised against N-domain of wild type HIF1α and does 
not recognize HIF1α1.2 due to it's different N-terminal part (Fig. 2a). 
Ab2 and Ab3 are monoclonal and polyclonal antibodies, respectively, 
with epitopes in the common parts of HIF1α and HIF1α1.2 (Fig.2a and 
b). Immunohistochemical analysis performed on thin adjacent sec-
tions of NE-differentiated prostate cancer using the HIF1α antibodies 
Ab1 (Fig. 2c), Ab 2 (Fig. 2d), Ab 3 (Fig. 2e) and HIF1β antibody (Fig. 2f). 
Immunopositivity was detected for HIF1α with Ab2 and Ab3 while 
HIF1α Ab1 produced no detectable staining. HIF1β was also positive in 
adjacent section (Fig. 2f). Double staining of chromogranin A and an-
drogen receptor antigens on adjacent sections (Fig. 2g) showed im-
munopositivity for chromogranin A (Fast red). Androgen receptor 
antibody (DAB, brown) produced no staining. Immunostaining of be-
nign prostate tissue with HIF1α Ab3 showed immunopositivity in NE-
like cells of benign prostate tissue (Fig. 2h). In addition, HIF1β antibody 
recognized benign NE-like cells in benign prostate hyperplasia (Fig. 2i). 
Double staining with HIF1α Ab3 and HIF1β (Fig. 2j) shows co-localiza-
tion of the two proteins in NE-like cells of benign prostate hyperplasia 
(HIF1α Ab3 red stain, HIF1β brown stain). Panels a, b, c, d, e, f and g: 40× 
objective. Panels h, i and j: 60× objective.
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malignant tumors, leading to hypoxia, inactivation of
prolyl hydroxylases and inhibition of HIF1α degradation,
which, in turn, activates HIF1α [19]. HIF1α protein has
also been shown to be stabilized under normoxic condi-
tions by growth factor stimulation or due to mutations in
the VHL protein [20]. The accumulation of HIF1α pro-
tein has been reported to be an early event in prostate
cancer and high-grade prostatic intraepithelial neoplasia
(HGPIN) [21,22]. The accumulation of wild type HIF1α
should lead to its nuclear transport, unless regulatory
parts are defective or missing. One possible explanation
for the cytoplasmic stabilization of the protein is the
presence of certain HIF1α isoforms. Indeed, in this study,
we have shown that a broad range of HIF1α isoforms are
present in both benign prostate hyperplasia and prostate
tumors. We have shown by PCR, immunohistochemistry
and in situ hybridization that the previously reported tes-
tis-specific isoform, HIF1α 1.2 corresponds to cytoplas-
mic HIF1α in NE-differentiated benign and malignant
prostate cells. HIF1α1.2, which lacks one of the NLS
domains responsible for nuclear transport, was shown to
accumulate in the cytoplasm and has also been shown in
a previous study to have inhibitory effects on full-length
HIF in human sperms [11]. The authors of that study
speculated that inhibition of full-length HIF1α might be
essential for the function of hypoxic sperm. A similar
function for cytoplasmic HIF1α in benign and malignant
prostate cells might be considered. In addition, co-local-
ization of cytoplasmic HIF1α and HIF1β in this study
indicates that this isoform might sequester HIF1β in the
cytoplasm. Other reports confirm a similar function for
cytoplasmic HIF1α. Stimulation of HEK293 cells with
zinc induces a cytoplasmic spliced variant of HIF1α with-
out exon 12 [23]. This 557-amino-acid isoform was
shown to sequester HIF1β in the cytoplasm and therefore
to inhibit wild type HIF1α. Due to a frame shift mutation,
the isoform is shortened and lacks both trans activating
domains and the C-terminal nuclear localizing signal
domain. Another cytoplasmic spliced variant of human
HIF1α (516 amino acids in length) represents a stable,
short isoform without exons 11 and 12 [14]. Similarly to
the variant lacking only exon 12, this isoform was identi-
fied as a dominant negative due to its association with
HIF1β in the cytoplasm.
Recent studies have shown an association between
hypoxia inducible factor and androgen receptor. The
androgen receptor activates HIF1α, leading to upregula-
tion of hypoxia inducible factor gene products [24,25]. In
addition, hypoxia has been shown to increase androgen
receptor sensitivity [26] and androgen receptor induced
expression of the human PSA gene in a prostate cancer
cell line [27]. Malignant NE cells which have been shown
to increase in number after hormonal treatment, are usu-
ally androgen independent and only occasionally express
androgen receptor and PSA [1]. As, we have shown here,
the NE differentiated tumor cells display an isoform with
a possible inhibitory effect on the wild type HIF1α pro-
tein, indicating that the androgen independent malignant
NE cells might also be independent of HIF1α for their
survival and tumorogenesis.
Malignant NE cells have been correlated with increased
microvessel density in prostate tumors and display
increased expression of VEGF, an important angiogenic
regulatory factor. The functional implication of cytoplas-
mic HIF1α and its relationship to VEGF remain to be elu-
cidated. HIF1α is a key regulatory transcription factor of
VEGF, but VEGF has also been shown to be regulated by
other transcriptions factors. For example, RaIA uppregu-
lates VEGF-C in prostate cancer cells during androgen
ablation [28] and STAT3 binds to the VEGF promoter
and directly regulates VEGF [29]. If cytoplasmic HIF1α in
NE cells exerts an inhibitory effect on full-length HIF1α,
this might indicate that VEGF is up-regulated in NE cells
by other transcription factors.
Figure 3 Results of in situ hybridization and immunohistochemis-
try on thin adjacent section to detect expression of HIF-1α1.2 
mRNA and HIF1α protein in malignant and benign prostate tis-
sue. In situ hybridization (antisense probe, Fig. 3a) and immunostain-
ing with HIF1α Ab2 (Fig. 3c) on thin adjacent sections of NE-
differentiated prostate adenocarcinoma showed co-localization of 
HIF1α1.2 transcript and HIF-1α protein. Incubation with sense probe 
did not generate any detectable hybridization signals (Fig. 3b). Both In 
situ hybridization (Fig. 3d antisense) and HIF-1α Ab2 immunostaining 
(Fig. 3f) were negative in non-NE-differentiated prostate adenocarci-
noma. In situ hybridization with sense probe performed on non-NE-dif-
ferentiated prostate cancer (Fig. 3e) was negative. In situ hybridizering 
on benign prostate tissue showed HIF1α1.2 transcript in NE-like cells of 
benign prostate tissue (Fig. 3g, κ). The sense probe on thin adjacent 
section generated no signals (Fig. 3h,κ). Furthermore, co-localization of 
HIF1α1.2 transcript (Fig. 3i,κ,ψ,Σ) and HIF1α protein, detected with 
HIF1αAb3 (Fig. 3j,κ,ψ,Σ) was also shown in NE-like cells of benign pros-
tate tissue. Panels a, b, c, d, e, f, g, h, i, j: 40× objective.
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In summary, our results suggest that cytoplasmic HIF1α
in androgen independent NE cells of benign prostate tis-
sue and non NE differentiated prostate tumors, corre-
sponds to HIF1α1.2 isoform. Co-localization of this
isoform with immunoreactive cytoplasmic HIF1β indi-
cates that the HIF1α 1.2 isoform, which lacks one of the
protein's nuclear translocation signals, may sequester
HIF1β in the cytoplasm.
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